Wang X., Ding Y.Q. Besides, the collected clinical trials involving TCM in the treatment of COVID-19 were mainly from China and published in Chinese, and thus further well-designed multicenter RCTs from different countries will be more attractive before a definitive conclusion can be drawn. Second, one purposes of this study was to retrieve information on adverse reactions from different countries, due to language barriers, only English and Chinese articles were retrieved, and adverse reactions in the Chinese population were specifically analyzed, the effects on populations from other countries therefore require further investigation. Study design was done by CH and BH. The quantitative analysis of all eligible studies. Systematic review of efficacy and safety of Lianhua Qingwen capsules in treatment of viral influenza. Lianhua Qingwen capsule and Lianhua Qingwen granules were approved to add "functional indications" to the originally approved indications: "In the conventional treatment of novel. Twenty-three studies on other diseases were included, with 12 reporting adverse reactions. Academician Yiling Wu systematically constructs the theory of collateral disease, provides theoretical guidance for the formulation of Lianhua Qingwen, and gives . Creative Commons Attribution License (CC BY). For hand-foot-mouth disease, sample size (p = 0.082), year of publication (p = 0.795), and treatment of the control group (p = 0.701) did not explain the issue of heterogeneity. The collected evidence demonstrated that LHQW exhibited benefits against COVID-19. The outcome measures included the alleviation of fever and other symptoms including nasal congestion, sore throat, cough, aches and pains, fatigue, headache, chills or sweats in subjects with acute uncomplicated influenza. Preferred Reporting Items for Systematic Reviews and Meta-Analyses: the PRISMA Statement. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher. Subgroup, sensitivity and meta-regression analyses were conducted to explore the possible sources of heterogeneity across eligible studies. Therefore, studies with blinded participants and personnel and blinded outcome assessments were classified as low risk of bias. In terms of incomplete outcome data and selective reporting, the majority of studies reported complete data on all symptom indicators with a low risk of attrition and reporting bias. [Efficacy and safety of Lianhua Qingwen capsule for influenza a doi:10.11954/ytctyy.201608076, Chan, K. W., Wong, V. T., and Tang, S. C. W. (2020). It argued that there was thus no reasonable basis for the mass distribution of the medication to healthy individuals to begin with, let alone doing so in a way that took up transportation capacity and resources that were urgently needed elsewhere. doi:10.1097/MD.0000000000026059, Gallelli, L., Ferreri, G., Colosimo, M., Pirritano, D., Guadagnino, L., Pelaia, G., et al. Lianhua Qingwen can be a complementary strategy for treating COVID-19. The complex components of LHQW stand for multiple targets and pleiotropic effects, but may also lead to more ADRs. 1 TABLE 1. (Jinyinhua), Ephedra sinica Stapf (Mahuang), Armeniacae Amarum Semen (Kuxingren), Gypsum Fibrosuum (Shigao), Isatis tinctoria L. (Banlangen), Dryopteridis Crassirhizomatis Rhizoma (Mianmaguanzhong), Houttuynia cordata Thunb. Till August 8, 2020, over 19,000,000 people have been confirmed infected and more than 700,000 people have died during this severe viral prevalence. Based Complement. No meta-regression was performed for COVID-19 pneumonia due to the limited number of studies. Yiling Pharmaceutical (2021). No adverse treatment-related effects were reported in all the included publications (from 2009 to 2011). Contraindications . Management of adverse reactions was clearly documented in 38 studies, which reported improvement or resolution through discontinuation of medication, changes to post-meal administration, symptomatic or no treatment. DerSimonian, R., and Laird, N. (1986). China Central Television News (2020). 327 (7414), 557560. A network analysis of the Chinese medicine Lianhua-Qingwen formula to identify its main effective components. From SARS to COVID-19: pathogens, receptor, pathogenesis and principles of the treatment. Furthermore, they identified two important metabolites, prostaglandin F2 and arachidonic acid, and their arachidonic acid metabolism pathway, as vital indicators of LHQW in treating influenza by using serum metabolomics analysis [19]. Pregnancy & lactation. Lianhua Qingwen Capsule for pneumonia treatment Pharmacol. For pooled studies, there was a significantly reduced risk of adverse reactions with LHQW group compared to the conventional drug group (RR = 0.63, 95% CI = 0.580.69, p < 0.001). Nevertheless, imperious researches should be conducted to clarify the unconfirmed effects, regulatory mechanisms and adverse reactions of LHQW in treating COVID-19 by means of well designed randomized controlled trials. LHQW also decreased the influenza viral titers in the lungs of mice, with decreased inflammatory cytokine levels in the early stages of infection [24]. The mechanisms were mainly involved the antiviral activity, and regulation of inflammation response as well as immune function. Front. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. 6 (01), 6364. We hope this review will not only present comprehensive evidence for LHQW use in COVID-19 therapy, but also fuel antiviral researches and put forward promising insights for further antiviral drug development. No proven effective antiviral treatments for COVID-19 pneumonia are available at present (Ahsan et al., 2020; Cao et al., 2020; Chan et al., 2020; Khan et al., 2020; Kupferschmidt and Cohen, 2020). The risk ratio (RR) and 95% confidence interval (CI) were calculated for categorical variables. Lianhua Qingwen is a commonly used Chinese patent medicine to treat viral infection. Further long-term high-quality studies are essential to validate our conclusions. Materia Med. Lu Y., Yang J., Wang X., Ma Z., Li S., Liu Z., Fan X. [19], Although the medicine has been allowed to be sold in Canada since 2012, Health Canada has cautioned against the use of the Chinese traditional medicine to prevent, treat, and cure COVID-19. The incidence of nervous system damage was lower in the LHQW group compared to the conventional drug group (RR = 0.24, 95% CI = 0.180.32, p < 0.001). Considerable research to date has focused on the clinical efficacy of LHQW, the safety of LHQW is additionally an important consideration for clinical application that should not be neglected. Recent clinical evidence also showed that LHQW in combination with western medicines, such as the other antiviral drugs, is better than that not using LHQW during COVID-19 treatment, suggesting it would be beneficial as a supplementary strategy for treating COVID-19 [41,[44], [45], [46]]. Beggs test and Eggers test detected no visible publication bias for data from pooled studies and disease evaluation. Accessibility 11 (31), 52605355. Several limitations of our meta-analysis should be taken into consideration. [7] In the United States, the FDA is advising consumers not to purchase or use Lianhua Qingwen, stating that it has not been approved or authorized by FDA and is being misleadingly represented as safe and/or effective for the treatment or prevention of COVID-19. Objectives: Lianhua Qingwen capsule/granule (LHQW) is an innovative patented traditional Chinese medicine with potential curative effects on respiratory diseases. doi:10.26434/chemrxiv.12016236.v1. (2010). Received: 27 August 2021; Accepted: 06 January 2022;Published: 27 January 2022. Race to Find Covid-19 Treatments Accelerates. Keywords: Lianhua Qingwen, adverse reaction, COVID-19, influenza, traditional Chinese medicine, meta-analysis, Citation: Hu C, He B, Gong F, Liang M, Zhao D and Zhang G (2022) The Adverse Reactions of Lianhua Qingwen Capsule/Granule Compared With Conventional Drug in Clinical Application: A Meta-Analysis. Drug-Use Hospitals China. Traditional Chinese medicine Lianhua Qingwen treating corona - PLOS Analysis of Clinical Application and Adverse Reactions of Houttuynia Cordata Injection. 343, d5928. Theoretical Study of the Anti-ncp Molecular Mechanism of Traditional Chinese Medicine Lianhua-Qingwen Formula (Lqf).
Darrell Jackson Jr Columbia, Sc,
Nc Stimulus Check When Is It Coming,
Articles L